The global hospital acquired disease testing market reached a value of US$ 7.32 Billion in 2020. Looking forward, IMARC Group expects the market to exhibit strong growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use industries. These insights are included in the report as a major market contributor.
Hospital acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and the emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Another reason can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patients’ own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.
The market for hospital acquired disease testing is currently exhibiting double digit growth rates. Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital acquired disease testing market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region and indication.
Market Breakup by Indication:
Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.
Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.
The global hospital acquired disease testing market size was valued at US$ 7.32 Billion in 2020.
According to the estimates by IMARC Group, the global hospital acquired disease testing market is expected to exhibit strong growth during 2021-2026.
Rising incidences of HAIs upon exposure to infected patients, contaminated linens, medical equipment, etc., are currently driving the market for hospital acquired disease testing.
Several technological advancements have led to the introduction of microarrays, solid phase hybridization, polymerase chain reaction (PCR) and real-time location systems (RTLSs) for detecting and monitoring HAIs, thereby representing the one of the key trends in the global hospital acquired disease testing market.
Sudden outbreak of the COVID-19 pandemic has led to the rising demand for advanced and effective testing devices for hospital acquired diseases based on the increasing risk of coronavirus contraction upon hospital visits.
On the basis of the indication, the market has been bifurcated into urinary tract infection, surgical site infection (SSI), pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus (MRSA), and others. Amongst these, urinary tract infection (UTI) holds the majority of the total market share.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
The key companies in the global hospital acquired disease testing market are Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at